Focus on Nivolumab in NSCLC

Immunotherapy is changing the treatment of non-small cell lung cancer (NSCLC). The PD-1 inhibitor nivolumab has demonstrated meaningful results in terms of efficacy with a good safety profile. The novel approach to treating NSCLC using immunotherapy still has unsolved questions and challenging issue...

Descripción completa

Detalles Bibliográficos
Autores principales: Cortinovis, Diego L., Canova, Stefania, Abbate, Marida, Colonese, Francesca, Bidoli, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2016
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153403/
https://www.ncbi.nlm.nih.gov/pubmed/28018902
http://dx.doi.org/10.3389/fmed.2016.00067

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153403/
https://www.ncbi.nlm.nih.gov/pubmed/28018902
http://dx.doi.org/10.3389/fmed.2016.00067

Ejemplares similares